Dr RR Baliga's "Got Knowledge Doc" Podkast

🚨 New insights from The Lancet 🚨

A major individual-patient-data meta-analysis (6 RCTs, 8,836 patients) shows that complete revascularisation in acute myocardial infarction significantly reduces cardiovascular death, all-cause mortality, and recurrent MI. 💓📉

Benefits were consistent across age, sex, STEMI/NSTEMI, and lesion characteristics — strengthening the case for a more comprehensive approach beyond the culprit lesion alone. 🔬🩺

A powerful reminder: treating the whole heart saves more lives. ❤️✨

🧬 New NEJM data on Olezarsen!

In patients with severe hypertriglyceridemia, monthly RNA-targeted therapy delivered major triglyceride reductions (−62% to −72%) and a significant drop in acute pancreatitis risk (rate ratio 0.15).

✨ Improvements extended to ApoC-III, remnant cholesterol, and non-HDL cholesterol, with consistent benefits across both CORE-TIMI trials.

💡 A promising step forward in precision lipid therapy and pancreatitis prevention.

📘 New Evidence from NEJM

In a large meta-analysis of 17,801 patients with preserved LVEF after MI, beta-blockers did not reduce death, recurrent MI, or heart failure. Event rates were low, and outcomes were similar with or without therapy. 🫀📊

This clarifies practice for a growing post-MI population with LVEF ≥50%—precision matters more than tradition. 🎯

Full study: New England Journal of Medicine (2025).

#Cardiology 💙 #ClinicalEvidence #MI #HeartHealth

📢 ADAPT AF-DES Trial — A Safer Path Forward!

In patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation, NOAC monotherapy delivered striking benefits over combination therapy.

✅ Lower net adverse clinical events

✅ Marked reduction in major/CRNM bleeding

✅ Similar ischemic protection

A beautifully simple strategy with meaningful impact.

Published in NEJM (2025).

💊🛡️📉💓

🌊 OCEAN Trial offers fresh insight into antithrombotic therapy after successful AF ablation. In 1284 patients followed for 3 years, event rates were remarkably low 🌟. Rivaroxaban did not show superiority over aspirin for preventing stroke, systemic embolism, or covert embolic events, while bleeding risk was higher with anticoagulation.

🧠 96% had no new infarcts on MRI at follow-up.

Published in NEJM (2025) — a valuable contribution to nuanced AF post-ablation care.

🧠 John Locke: Experience • Liberty • Toleration

Born a physician-philosopher, Locke championed empiricism — the idea that knowledge begins with experience, not dogma. His tabula rasa shaped modern psychology, while his Two Treatises of Government defined rights, consent, and freedom that echo through modern democracies.

For clinicians, his legacy reminds us to:

🔹 Trust observation and evidence over authority

🔹 Respect patient autonomy and informed consent

🔹 Foster pluralism and toleration in care

His vision of reason and tolerance remains medicine's quiet ally.

🕊️📜💬 Observation. Reflection. Compassion.

🚀 VESALIUS-CV delivers powerful evidence: in high-risk patients without prior MI or stroke, evolocumab significantly reduced 3-point MACE by 25% and 4-point MACE by 19%, with LDL-C lowered to a median of 45 mg/dL.

💡 These results expand the horizon of prevention, showing that deep LDL reduction is both safe and effective in averting first cardiovascular events.

🫀 Strong science. Clear signal. A new chapter in preventive cardiology.

#Cardiology #LDL #Prevention #VESALIUSCV

🫀 Septic Shock, Refined at the Fingertips ⏱️

A powerful new JAMA (2025) trial brings us one step closer to truly personalized resuscitation. The ANDROMEDA-SHOCK-2 study shows that targeting capillary refill time (CRT) — a simple bedside sign — can shorten time on organ support vs usual care, without increasing mortality.

Key insight: Sometimes the most elegant solutions are low-tech, high-touch, and right at the bedside.

🧠 Precision

🤚 Physiology

💡 Pragmatism

#Sepsis #CriticalCare #PersonalizedMedicine #JAMA #Hemodynamics #ICU #Shock

🚨 SOFA-2 arrives — a thoughtful evolution in critical care scoring 🧠🫁🫀

After nearly 30 years, the SOFA score has been modernized using data from >3.3 million ICU patients across 9 countries. The updated SOFA-2 incorporates contemporary respiratory and cardiovascular supports (HFNC, NIPPV, vasopressors, ECMO) and refines thresholds while preserving simplicity and bedside usability.

A meaningful step forward in describing organ dysfunction — with room for future biologically grounded refinement.

📖 Published in JAMA

SOFA-2 is here — a major advance in assessing organ dysfunction in critical illness 🧠🫁❤️

Three decades after the original SOFA score, this updated framework reflects modern ICU practice — integrating contemporary organ support (ventilation, vasopressors, RRT), delirium recognition, and global feasibility across resource settings 🌍📊

Validated in 3.3M+ ICU patients across 9 countries — a remarkable effort in global critical care science 🏥📈

A powerful step forward in our shared language of severity and recovery.

🔗 JAMA Network Open, 2025